Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Re (RMAX) Research & Development (2024 - 2025)

Re (RMAX) has disclosed Research & Development for 2 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 123.3% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Dec 2025, up 1307.03% year-over-year, with the annual reading at $13.0 million for FY2025, 378.72% up from the prior year.
  • Research & Development for Q4 2025 was $2.5 million at Re, down from $2.6 million in the prior quarter.
  • The five-year high for Research & Development was $8.1 million in Q1 2024, with the low at -$10.9 million in Q4 2024.